payable for investment purchases in MTS and COMASS of THB 220mn and THB 90mn, respectively. 2Q 2016 2Q 2017 2Q 20171 2Q 2016 2Q 2017 2Q 20171 Profitability Ratios Liquidity Ratios Gross profit 2 (%) 53.0

. In , the patients accepted replacement therapy with dialysis with dialysis machines increased steadily to fully capacity. In , the Company purchases dialysis machines to accommodate more patients. In

person who purchases or redeems the investment units with incorrect unit price, or any payment with a value equivalent to the difference between the incorrect unit price and the correct unit price in lieu

purchases or redeems the investment units with incorrect unit price, or any payment with a value equivalent to the difference between the incorrect unit price and the correct unit price in lieu of the

company. “Unit price” means a selling price or redemption price of investment units. “Price compensation” means an increase or decrease in the number of investment units of any person who purchases or

million from 31 December 2017 or 3.59%, due to as follows: (1) Cash, cash equivalents and current investments decreased THB 786.73 million due to the Company increase in its purchases of program rights in

. General characteristics of the transaction size and the transaction details of the assets. 3.1 Transaction Details The Company purchases shares of the BS Myco Biotech Company Limited which is a company that

its purchases of program rights in 2018 in order to support the growth of business and operating results of the Company and the repayment of short-term borrowings from financial institutions in order to

shareholders’ equity was mainly derived from (1) Net profit during the period THB 28.5 Mn and (2) Disposal of discount on purchases of fixed assets from companies under common control THB 0.2 Mn. Cash Flow

from financial institutions of THB 320mn. Net cash used in investing activities was THB 361mn, mainly from cash paid for 1) purchases of investments in associate of THB 283mn and 2) acquisition of